Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 12:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 497 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Elevated Cardiovascular Risk Clear all
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975389
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
518
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Phase 2 Interventional

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

NCT00003658
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, pentostatin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 4, 2026, 12:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Potassium Supplementation Study

NCT05887622
View directory record Official record
Conditions
Cardiovascular Health, Cardiovascular Risk Factor
Interventions
Potassium chloride supplement, Placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 4, 2026, 12:09 AM EDT
Withdrawn Phase 2 Interventional

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

NCT03003728
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803
Drug · Procedure · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 4, 2026, 12:09 AM EDT
Completed No phase listed Observational

SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy

NCT00403078
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Not listed
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
21,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Newark, Delaware • West Des Moines, Iowa • Lincoln, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 4, 2026, 12:09 AM EDT
Terminated Early Phase 1 Interventional Results available

L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia

NCT03542812
View directory record Official record
Conditions
Infant,Premature, Bronchopulmonary Dysplasia, Pulmonary Hypertension
Interventions
L-Citrulline
Drug
Lead sponsor
University of Utah
Other
Eligibility
14 Days to 3 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 4, 2026, 12:09 AM EDT
Completed No phase listed Observational

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

NCT04864795
View directory record Official record
Conditions
Heart Failure, Hyperkalemia
Interventions
Not listed
Lead sponsor
Vifor (International) Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
52
States / cities
Little Rock, Arkansas • La Jolla, California • Northridge, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habitual Diet and Avocado Trial

NCT03528031
View directory record Official record
Conditions
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions
Intervention Daily Avocado
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years and older
Enrollment
1,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Not applicable Interventional

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

NCT01931852
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Cardiac MRI, ACC/AHA Guideline adherent care
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Royal Oak, Michigan • Jackson, Mississippi • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 4, 2026, 12:09 AM EDT
Recruiting No phase listed Observational

Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR

NCT05862558
View directory record Official record
Conditions
Iliac Disease, Aortic Valve Stenosis
Interventions
Shockwave Balloon
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Phase 2 Interventional

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

NCT00570752
View directory record Official record
Conditions
Vascular Diseases
Interventions
Placebo, BMS-582949, Atorvastatin, Statin
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 4, 2026, 12:09 AM EDT
Terminated Phase 2 Interventional Results available

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

NCT01534143
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
pharmacological study, tacrolimus, sirolimus, anti-thymocyte globulin, fludarabine phosphate, busulfan, bortezomib, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
Other · Drug · Biological + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 4, 2026, 12:09 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Months and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 12:09 AM EDT
Terminated No phase listed Observational

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
21,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 4, 2026, 12:09 AM EDT
Recruiting Phase 2 Interventional

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

NCT06100237
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Not applicable Interventional

Focused Palliative Care Intervention in Advanced Heart Failure

NCT02805712
View directory record Official record
Conditions
Heart Failure, Quality of Life
Interventions
Verbal Information and Discussion, Control
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 4, 2026, 12:09 AM EDT
Completed Not applicable Interventional Results available

Postpartum Weight Loss for Women at Elevated Cardiovascular Risk

NCT04914819
View directory record Official record
Conditions
Weight Loss, Postpartum Weight Retention, Hypertension in Pregnancy, Diabetes Mellitus in Pregnancy, Preeclampsia, Recruitment
Interventions
Online Behavioral Weight Loss Program, Virtual weigh-in
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 4, 2026, 12:09 AM EDT
Recruiting Not applicable Interventional

Physician-Modified Endografts for Complex Aortic Aneurysms and Thoracoabdominal Aneurysm Repair in High-Risk Patients

NCT07224230
View directory record Official record
Conditions
Abdominal Aortic Aneurysms, Thoracoabdominal Aneurysms, Pararenal Aortic Aneurysm
Interventions
Physician Modified Endograft
Device
Lead sponsor
Steven Maximus
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 4, 2026, 12:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Delta GREENS Food is Medicine Intervention

NCT06358859
View directory record Official record
Conditions
Cardiometabolic Risk Factors, Diabetes, High Blood Pressure, Obesity, Nutrition Security
Interventions
Food is Medicine
Other
Lead sponsor
Tufts University
Other
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 4, 2026, 12:09 AM EDT
Terminated Phase 2 Interventional Results available

CART-19 Post-ASCT for Multiple Myeloma

NCT02794246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CART-19 cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 4, 2026, 12:09 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

NCT01734694
View directory record Official record
Conditions
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
Interventions
Vancomycin, Ceftaroline, Daptomycin, Linezolid
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 4, 2026, 12:09 AM EDT